Formation of angiotensin III from [des-Asp1]angiotensin I in the mesentric vasculature. 1979

J M Sexton, and S L Britton, and W H Beierwaltes, and M J Fiksen-Olsen, and J C Romero

The effects of [des-Asp1]angiotensin I and angiotensin III on mesenteric blood flow were compared in 15 pentobarbital-anesthetized dogs. These agonists were administered as bolus injections directly into the vasculature supplied by the superior mesenteric artery. Both [des-Asp1]angiotensin I and angiotensin III produced dose-dependent decreases in mesenteric blood flow, with angiotensin III being more potent than [des-Asp1]angiotensin I at all doses tested. The constrictor responses to [des-Asp1]angiotensin I were markedly attenuated in the presence of an angiotensin-converting enzyme inhibitor (SQ20881); SQ20881 did not alter responses to angiotensin III or norepinephrine. The administration of [Ile7]angiotensin III (an angiotensin III antagonist) attenuated the responses to both [des-Asp1]angiotensin I and angiotensin III, without altering the responses to norepinephrine. These results suggest that the decrease in mesenteric blood flow produced by [des-Asp1]angiotensin I is largely caused by its local enzymatic conversion to angiotensin III. This conversion in one transit through the mesenteric vasculature is approximately 24%.

UI MeSH Term Description Entries
D008297 Male Males
D008638 Mesenteric Arteries Arteries which arise from the abdominal aorta and distribute to most of the intestines. Arteries, Mesenteric,Artery, Mesenteric,Mesenteric Artery
D008643 Mesentery A layer of the peritoneum which attaches the abdominal viscera to the ABDOMINAL WALL and conveys their blood vessels and nerves. Mesenteries
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D000803 Angiotensin I A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000805 Angiotensin III A heptapeptide formed from ANGIOTENSIN II after the removal of an amino acid at the N-terminal by AMINOPEPTIDASE A. Angiotensin III has the same efficacy as ANGIOTENSIN II in promoting ALDOSTERONE secretion and modifying renal blood flow, but less vasopressor activity (about 40%). Des-Asp Angiotensin II,Des-Aspartyl-Angiotensin II,Angiotensin II, Des-Asp,Des Asp Angiotensin II,Des Aspartyl Angiotensin II

Related Publications

J M Sexton, and S L Britton, and W H Beierwaltes, and M J Fiksen-Olsen, and J C Romero
December 1975, Journal of medicinal chemistry,
J M Sexton, and S L Britton, and W H Beierwaltes, and M J Fiksen-Olsen, and J C Romero
December 1980, Endocrinology,
J M Sexton, and S L Britton, and W H Beierwaltes, and M J Fiksen-Olsen, and J C Romero
May 1979, Circulation research,
J M Sexton, and S L Britton, and W H Beierwaltes, and M J Fiksen-Olsen, and J C Romero
January 1982, Clinical and experimental pharmacology & physiology. Supplement,
J M Sexton, and S L Britton, and W H Beierwaltes, and M J Fiksen-Olsen, and J C Romero
September 1977, Endocrinology,
J M Sexton, and S L Britton, and W H Beierwaltes, and M J Fiksen-Olsen, and J C Romero
December 1975, The Journal of clinical endocrinology and metabolism,
J M Sexton, and S L Britton, and W H Beierwaltes, and M J Fiksen-Olsen, and J C Romero
November 1994, Biological & pharmaceutical bulletin,
J M Sexton, and S L Britton, and W H Beierwaltes, and M J Fiksen-Olsen, and J C Romero
May 1977, Circulation research,
J M Sexton, and S L Britton, and W H Beierwaltes, and M J Fiksen-Olsen, and J C Romero
January 1980, The Journal of clinical endocrinology and metabolism,
J M Sexton, and S L Britton, and W H Beierwaltes, and M J Fiksen-Olsen, and J C Romero
July 1976, European journal of pharmacology,
Copied contents to your clipboard!